Entwicklung eines systemischen Lupus erythematodes mit fokaler proliferativer Lupusnephritis unter einer Anti-TNF-α-Therapie bei Psoriasisarthritis

Haake, Hendrik; Koneke, J.; Amann, Kerstin; Dahl, Jürgen vom; Janssen, Ulf

doi:10.1007/s00063-007-1104-6

Cited by 17 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although previous observations suggested a possible beneficial role of TNF‐α inhibitors in the treatment of GN,101–104 more recent reports and greater experience with utilization of TNF‐α inhibitors raise intriguing questions concerning not only TNF‐α inhibitors efficacy in GN, but also demonstrating a possible causative role in the emergence of renal complications such as GN. To our knowledge, GN occurred in at least 19 patients (most of them developing lupus nephritis), during treatment with anti‐TNF‐α105–113 (Table 2).…”

Section: Tnf‐α Inhibitorsmentioning

confidence: 99%

Renal manifestations and complications of inflammatory bowel disease

Oikonomou¹,

Kapsoritakis²,

Eleftheriadis

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Renal manifestations and complications are not rare in patients with inflammatory bowel disease (IBD) and may present as nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis. Symptoms of renal impairment are not always specific and since the underlying bowel disease is preponderant, renal function deterioration may be underestimated. Additionally, medical treatment of patients with IBD such as aminosalicylates, cyclosporine, and tumor necrosis factor-α inhibitors can cause renal complications, although direct correlation to bowel disease is not always clear. The well-documented renal manifestations and complications of IBD, as well as the possible renal side effects of new drugs, emphasize the need for periodic evaluation of renal function. New markers of renal function may facilitate early diagnosis and unravel the complex mechanisms responsible for kidney damage. The purpose of this review is to summarize the renal manifestations and complications as well as the markers of renal function utilized in IBD, attempting to shed more light on the pathophysiology of renal damage in IBD.

show abstract

Section: Tnf‐α Inhibitorsmentioning

confidence: 99%

Renal manifestations and complications of inflammatory bowel disease

Oikonomou¹,

Kapsoritakis²,

Eleftheriadis

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…These findings were also reflected in another comparison of disability and QoL between patients with RA and patients with PsA; this study reported that despite greater peripheral joint damage in patients with RA the function and QoL scores were similar for both groups. 27,28 These reveal that there might be unique psychological disabilities associated with the psoriasis dimension (i.e. skin lesion) of PsA.…”

Section: Significance In Terms Of Ill Healthmentioning

confidence: 99%

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Rodgers

Epstein²,

Bojke³

et al. 2011

Health Technol Assess

155

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of pro...

show abstract

“…Furthermore, anti TNFα can be effective in the treatment of renal amyloidosis in patients with IBD. However, anti TNFα can contribute to renal injury and may directly cause glomerulonephritis or lupus nephritis [53,54].…”

Section: Azathioprine and Mercaptopurinementioning

confidence: 99%

Renal involvement in paediatric inflammatory bowel disease

Mutalib

2019

Pediatr Nephrol

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), which includes Crohn's disease, ulcerative colitis and inflammatory bowel disease unclassified, is a chronic inflammatory disorder that predominantly affects the gastrointestinal (GI) tract and has a rising incidence in both children and adults. Symptoms are caused by inappropriate inflammatory response triggered by interaction between the environment, gut microbiome and host immune system in a genetically susceptible individual. Extranintestinal manifestations of IBD are common and can affect any body system outside the gut; they can precede or run parallel to GI inflammation. Renal involvement in IBD is uncommon and can be part of extraintestinal manifestation or metabolic complications of IBD. Many medications used to treat IBD can cause renal damage. Renal manifestation in children with IBD can range from asymptomatic biochemical abnormalities to variable stages of renal impairment with significant morbidity and even mortality burden.

show abstract

Entwicklung eines systemischen Lupus erythematodes mit fokaler proliferativer Lupusnephritis unter einer Anti-TNF-α-Therapie bei Psoriasisarthritis

Cited by 17 publications

References 17 publications

Renal manifestations and complications of inflammatory bowel disease

Renal manifestations and complications of inflammatory bowel disease

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Renal involvement in paediatric inflammatory bowel disease

Contact Info

Product

Resources

About